Clinical Cancer Research CR Balducci Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 2514, April 15, 2008. doi: 10.1158/1078-0432.CCR-07-4979
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oudejans, J. J.
Right arrow Articles by Meijer, C. J.L.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oudejans, J. J.
Right arrow Articles by Meijer, C. J.L.M.

Letters to the Editor

T-Cell Response in B-Cell Lymphomas: Favorable or Unfavorable?

Joost J. Oudejans, Jettie J.F. Muris, Saskia A.G.M. Cillessen and Chris J.L.M. Meijer

Department of Clinical Pathology, VU University Medical Center, Amsterdam, the Netherlands

To the Editors: In a recent issue of Clinical Cancer Research, Chang and colleagues reported that in patients with diffuse large B-cell lymphoma, the presence of an intense cytotoxic T-cell infiltrate was associated with a favorable clinical outcome (1). These observations are in contrast with our previous reports, and by other reports, which show that the presence of many activated cytotoxic T-cells in primary nodal diffuse large B-cell lymphomas is in fact a strong International Prognostic Index–independent indicator for an unfavorable clinical outcome (2, 3). We recently confirmed this association by microarray expression analysis, which also identified a group of patients with primary nodal diffuse large B-cell lymphoma with a very poor clinical outcome that was characterized by high expression levels of cytotoxic T-cell effector molecules including granzyme B and perforin (4). The possible causes for these conflicting data are not clear but could result from differences in the methods used for quantification of the T cells or by selection of analyzed areas of tumor specimens.

It is unclear why Chang et al. did not cite these previous articles. Chang et al. conclude that enhancing this putative antitumor T-cell immune response is a possible target for diffuse large B-cell lymphoma immunotherapy (1). Based on our data, and the data reported by Hasselblom et al. (3), we think that this is unlikely. Apparently, in cases with many activated CTLs, these T cells are also incapable of effectively killing the lymphoma cells. Hasselblom et al. showed that this is probably not caused by the presence of Foxp3 immunosuppressive T cells (3). We have previously suggested that lymphoma cells might escape from CTL-induced apoptosis not only by interfering with proper antigen presentation but also by disruption of the intracellular apoptosis pathway (2). This latter mechanism could also explain the poor response to the apoptosis-inducing chemotherapy. Thus, from this point of view, not enhancing the antilymphoma T-cell response, but rather, restoring apoptosis sensitivity will be a promising new therapy for patients with chemotherapy-refractory diffuse large B-cell lymphoma. Recently, we have shown that this is indeed a highly promising approach (5).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

  1. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007;13:6666–72.[Abstract/Free Full Text]
  2. Muris JJ, Meijer CJ, Cillessen SA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004;18:589–96.[CrossRef][Medline]
  3. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137:364–73.[CrossRef][Medline]
  4. Muris JJ, Ylstra B, Cillessen SA, et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol 2007;136:38–47.[CrossRef][Medline]
  5. Cillessen SA, Reed JC, Welsh K, et al. Small-molecule XIAP antagonist restores caspase-9-mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 2008;111:369–75.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oudejans, J. J.
Right arrow Articles by Meijer, C. J.L.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oudejans, J. J.
Right arrow Articles by Meijer, C. J.L.M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online